Grants > Pilot Study Of Bumetanide For Refractory Neonatal
 

2007

Quest Awards

Pilot Study Of Bumetanide For Refractory Neonatal

Janet Soul, MD, CM
Children’s Hospital Boston and Harvard Medical School/ Boston, MA
 

Newborn babies have seizures much more frequently than either children or adults, and their seizures are often associated with serious long-term consequences such as epilepsy, learning disabilities and cerebral palsy. Although newborn seizures are very common, medications currently used to treat them are relatively ineffective and may have serious side effects. A medication called bumetanide shows great promise for treating newborn seizures because the drug blocks special channels present only in the brain cells of newborns. We will conduct a pilot trial to determine whether bumetanide is a safe drug for the treatment of newborn seizures.

    STAY UP TO DATE

    Join our email list for the
    latest epilepsy research news,
    discoveries, and more.